31 results
8-K
EX-99.2
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
-based awards at the grant date. We estimate the fair value of our stock-based awards using the Black-Scholes option-pricing model which requires inputs
8-K
EX-99.1
TRML
Tourmaline Bio Inc
14 Nov 23
Index to Unaudited Condensed Financial Statements
5:15pm
Dividend yields
Volatility
Expected term (in years)
Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock
425
j43e0v
26 Sep 23
Business combination disclosure
8:24am
8-K
EX-99.1
ktbb 2nwht
26 Sep 23
Regulation FD Disclosure
8:21am
425
q68b5 o6j
13 Sep 23
Business combination disclosure
9:14am
8-K
EX-99.1
3jfz3
13 Sep 23
Regulation FD Disclosure
9:13am
CORRESP
wj2uxaa4mo 8cuqa0e
25 Aug 23
Correspondence with SEC
12:00am
UPLOAD
l6gnaiqko2wfzzj
16 Aug 23
Letter from SEC
12:00am
8-K
EX-99.2
5tz svc6d2f
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am
8-K
EX-99.1
abihg0l 0aviw
30 Jun 22
Other Events
4:54pm